Advantage Alpha Capital Partners LP Catalyst Pharmaceuticals, Inc. Transaction History
Advantage Alpha Capital Partners LP
- $361 Million
- Q1 2025
A detailed history of Advantage Alpha Capital Partners LP transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 20,037 shares of CPRX stock, worth $420,175. This represents 0.13% of its overall portfolio holdings.
Number of Shares
20,037
Previous 13,050
53.54%
Holding current value
$420,175
Previous $272,000
78.31%
% of portfolio
0.13%
Previous 0.07%
Shares
4 transactions
Others Institutions Holding CPRX
# of Institutions
383Shares Held
99.5MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$392 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$178 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$116 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$71.8 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$65.8 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.16B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...